Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

November 30, 2024

Study Completion Date

December 30, 2024

Conditions
Ocular Surface SymptomOcular Surface DiseaseEye PainEye Inflammation
Interventions
DRUG

Group 1 drug

Group 1: In this group, the aim is to compare 2 drugs, cyclosporine 0.05% and Lifitgrast . In one eye, cyclosporine 0.05% eye drops are randomly poured and in the opposite eye, Lifitgrast eye drops are poured.

DRUG

Group 2: Drug and placebo

Group 2: In this group, the aim is to compare 2 drugs, cyclosporine 0.05% and Artelac artificial tear as a placebo. In one eye, cyclosporine 0.05% eye drops are randomly poured, and in the opposite eye, Artelac artificial tear are poured.

DRUG

Group 3: Drug and palcebo

Group 3: In this group, the aim is to compare 2 drugs, Lifitgrast and Artelac artificial tear as a placebo. In one eye, Lifitgrast eye drops are randomly poured, and in the opposite eye, Artelac artificial tear are poured.

Trial Locations (1)

Unknown

Isfahan University of Medical Sciences, Feiz Hospital, Isfahan, Isfahan

All Listed Sponsors
lead

Mohsen Pourazizi

OTHER

NCT06624384 - Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024 | Biotech Hunter | Biotech Hunter